Literature DB >> 29935386

Correlating quantitative tumor accumulation and gene knockdown using SPECT/CT and bioluminescence imaging within an orthotopic ovarian cancer model.

Steven K Jones1, Kirk Douglas2, Anthony F Shields2, Olivia M Merkel3.   

Abstract

Using an orthotopic model of ovarian cancer, we studied the delivery of siRNA in nanoparticles of tri-block copolymers consisting of hyperbranched polyethylenimine-graft-polycaprolactone-block-poly(ethylene glycol) (hyPEI-g-PCL-b-PEG) with and without a folic acid targeting ligand. A SKOV-3/LUC FRα overexpressing cell line was employed to mimic the clinical manifestations of ovarian cancer. Both targeted and non-targeted micelleplexes were able to effectively deliver siRNA to the primary tumor and its metastases, as measured by gamma scintillation counting and confocal microscopy. Stability of the micelleplexes was demonstrated with a serum albumin binding study. Regarding biodistribution, intravenous (I.V.) administration showed a slight advantage of FRα targeted over non-targeted micelleplex accumulation within the tumor. However, both formulations displayed significant liver uptake. On the other hand, intraperitoneally (I.P.) injected mice showed a modest 6% of the injected dose per gram (ID/g) uptake within the primary and most interestingly also in the metastatic lesions which subsequently resulted in a 62% knockdown of firefly luciferase expression in the tumor after a single injection. While this is, to the best of our knowledge, the first paper that correlates quantitative tumor accumulation in an orthotopic tumor model with in vivo gene silencing, these data demonstrate that PEI-g-PCL-b-PEG-Fol conjugates are a promising option for gene knockdown in ovarian cancer.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Folate receptor alpha; Folate receptor targeting; Ovarian cancer; Ovarian cancer xenograft; Polymer micelleplexes; siRNA delivery

Mesh:

Substances:

Year:  2018        PMID: 29935386      PMCID: PMC6056733          DOI: 10.1016/j.biomaterials.2018.06.014

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  57 in total

Review 1.  Delivery of siRNA therapeutics: barriers and carriers.

Authors:  Jie Wang; Ze Lu; M Guillaume Wientjes; Jessie L-S Au
Journal:  AAPS J       Date:  2010-06-11       Impact factor: 4.009

2.  Ovarian cancer development and metastasis.

Authors:  Ernst Lengyel
Journal:  Am J Pathol       Date:  2010-07-22       Impact factor: 4.307

3.  Revisiting the value of competition assays in folate receptor-mediated drug delivery.

Authors:  Steven K Jones; Anwesha Sarkar; Daniel P Feldmann; Peter Hoffmann; Olivia M Merkel
Journal:  Biomaterials       Date:  2017-05-22       Impact factor: 12.479

Review 4.  Membrane transporters and channels in chemoresistance and -sensitivity of tumor cells.

Authors:  Ying Huang; Wolfgang Sadée
Journal:  Cancer Lett       Date:  2005-10-05       Impact factor: 8.679

5.  Multifunctional nanoparticles delivering small interfering RNA and doxorubicin overcome drug resistance in cancer.

Authors:  Yunching Chen; Surendar Reddy Bathula; Jun Li; Leaf Huang
Journal:  J Biol Chem       Date:  2010-05-11       Impact factor: 5.157

6.  Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay.

Authors:  Nikki Parker; Mary Jo Turk; Elaine Westrick; Jeffrey D Lewis; Philip S Low; Christopher P Leamon
Journal:  Anal Biochem       Date:  2005-03-15       Impact factor: 3.365

7.  Alpha-folate receptor expression in epithelial ovarian carcinoma and non-neoplastic ovarian tissue.

Authors:  Susanne Markert; Silke Lassmann; Boris Gabriel; Maximilian Klar; Martin Werner; Gerald Gitsch; Felix Kratz; Annette Hasenburg
Journal:  Anticancer Res       Date:  2008 Nov-Dec       Impact factor: 2.480

8.  Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles.

Authors:  Mark E Davis; Jonathan E Zuckerman; Chung Hang J Choi; David Seligson; Anthony Tolcher; Christopher A Alabi; Yun Yen; Jeremy D Heidel; Antoni Ribas
Journal:  Nature       Date:  2010-03-21       Impact factor: 49.962

9.  Amphiphilic biodegradable PEG-PCL-PEI triblock copolymers for FRET-capable in vitro and in vivo delivery of siRNA and quantum dots.

Authors:  Thomas Endres; Mengyao Zheng; Ayşe Kılıç; Agnieszka Turowska; Moritz Beck-Broichsitter; Harald Renz; Olivia M Merkel; Thomas Kissel
Journal:  Mol Pharm       Date:  2014-03-12       Impact factor: 4.939

Review 10.  Animal models of ovarian cancer.

Authors:  Barbara C Vanderhyden; Tanya J Shaw; Jean-François Ethier
Journal:  Reprod Biol Endocrinol       Date:  2003-10-07       Impact factor: 5.211

View more
  3 in total

Review 1.  Strategies for Delivery of siRNAs to Ovarian Cancer Cells.

Authors:  Rossella Farra; Matea Maruna; Francesca Perrone; Mario Grassi; Fabio Benedetti; Marianna Maddaloni; Maguie El Boustani; Salvo Parisi; Flavio Rizzolio; Giancarlo Forte; Fabrizio Zanconati; Maja Cemazar; Urska Kamensek; Barbara Dapas; Gabriele Grassi
Journal:  Pharmaceutics       Date:  2019-10-22       Impact factor: 6.321

Review 2.  Image-guided mathematical modeling for pharmacological evaluation of nanomaterials and monoclonal antibodies.

Authors:  Prashant Dogra; Joseph D Butner; Sara Nizzero; Javier Ruiz Ramírez; Achraf Noureddine; María J Peláez; Dalia Elganainy; Zhen Yang; Anh-Dung Le; Shreya Goel; Hon S Leong; Eugene J Koay; C Jeffrey Brinker; Vittorio Cristini; Zhihui Wang
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2020-04-21

Review 3.  RNA Drug Delivery Using Biogenic Nanovehicles for Cancer Therapy.

Authors:  Nuannuan Li; Yiying Sun; Yuanlei Fu; Kaoxiang Sun
Journal:  Front Pharmacol       Date:  2021-12-24       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.